
Hydrolases and uses thereof

BRIEF DESCRIPTION OF A TECHNOLOGY

This technology presents a novel enzyme-prodrug system for targeted cancer therapy based on bacterial cytidine deaminases CDA_EH, CDA_F14, and CDA_Lsp. These enzymes efficiently activate non-toxic 5-fluoropyrimidine nucleoside prodrugs by converting them into cytotoxic metabolites such as 5-fluorouridine and 5-fluoro-2'-deoxyuridine. In contrast to human CDA, the bacterial variants display broader substrate specificity and higher activity, activating a wider range of modified prodrugs. Tested in cancer cell models, the enzyme-prodrug combinations demonstrated potent, selective cytotoxicity, highlighting their potential as next-generation therapeutic tools for precision oncology.



PURPOSE

This technology aims to develop a targeted cancer therapy platform in which bacterial cytidine deaminases selectively activate non-toxic prodrugs inside tumor cells, producing cytotoxic metabolites locally to maximize anticancer efficacy while minimizing systemic side effects.

FIELDS OF APPLICATION

Applications of this technology range from next-generation cancer therapies to the development of innovative fluoropyrimidine drugs. It enables gene-directed approaches, accelerates precision oncology solutions, and offers a versatile platform for screening and validating new prodrug candidates.

TECHNOLOGY READINESS

Technology validated in lab (TRL 4).

INTELLECTUAL PROPERTY

Patent application: EP4299736 (A3). Applicant: Vilnius University.

RELEVANT PUBLICATIONS

Preitakaité et al. (2025) Eur J Med Chem., DOI: 10.1016/j.ejmech.2025.117860.

INVENTORS

- Rolandas MESKYS
- Nina URBELIENE
- Daiva TAURAITE
- Matas TISKUS
- Viktorija PREITAKAITE



CONTACTS

Dr. Viktorija Preitakaitė Institute of Biochemistry, Life Sciences Center, Vilnius University E-mail:

viktorija.preitakaite@gmc.vu.lt Phone: +370 6 966 7803

Dr. Ramūnas Grigonis
Innovation Office, Department
for Research and Innovation,
Vilnius University
E-mail:

ramunas.grigonis@cr.vu.lt Phone: +370 5 268 7006